Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Cost of clindamycin without insurance?

See the DrugPatentWatch profile for clindamycin

Prices without insurance vary a lot by country, pharmacy, and which form you need (oral capsules vs topical/vaginal forms). Here are rough US cash-price ranges to give you a ballpark:

- Oral clindamycin capsules (generic)
- 150 mg: roughly $12–$40 for a typical 20–60 capsule bottle
- 300 mg: roughly $15–$50 for a typical 60– capsule bottle

- Topical clindamycin products (e.g., 1% gel/solution, brand-name products tend to be higher)
- Generally in the range of about $60–$150 for a supply (varies by size and exact product)

- Vaginal clindamycin products (generics/brand)
- Often around $70–$150+ depending on strength and size

Tips to save money:
- Ask for the generic version first.
- Compare prices at multiple pharmacies or use price-comparison tools (e.g., GoodRx, SingleCare) and show pharmacist the lowest price.
- Check if your doctor can prescribe a different but equivalent antibiotic if cost is a barrier and it’s clinically appropriate.
- Look for pharmacy loyalty programs or manufacturer coupons.

If you tell me your country and the exact form and strength you need (for example: oral 150 mg capsules, or topical 1% gel), I can give you a tighter estimate or help you look up current prices for your area.



Other Questions About Clindamycin :

Clindamycin coverage? Clindamycin benzoyl peroxide coupon? Clindamycin phosphate and benzoyl peroxide market? Clindamycin category class? Clindamycin iv? Clindamycin benzoyl peroxide price? Clindamycin generic names?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The provided claim summary is consistent with the supplied FDA label excerpts: clindamycin should be used only for proven/strongly suspected susceptible bacterial infections and not for viral/nonbacterial infections, aligning with the INDICATIONS AND USAGE and PRECAUTIONS statements. No contradictions or omitted material safety elements are identifiable from the information provided.


Category Scores

Indication
100
Excellent
Warnings
90
Excellent

Accurate Statements

Clindamycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria; prescribing in the absence of such infection is unlikely to provide benefit and increases risk of drug-resistant bacteria.
Section 1 (Indications and Usage) and Section 5 (PRECAUTIONS / General / Information for Patients): “should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria” and “Prescribing clindamycin injection in the absence of a proven or strongly suspected bacterial infection… is unlikely to provide benefit… and increases the risk of… drug-resistant bacteria.”
Antibacterial drugs including clindamycin should be used only to treat bacterial infections and do not treat viral infections.
Section 5 (PRECAUTIONS / General / Information for Patients): “They do not treat viral infections (e.g., the common cold).”

Unsupported Statements


Contradictions


Important Omissions

Boxed warning content regarding C. difficile-associated diarrhea/colitis was included in the prompt label excerpts but was not reflected in any explicit AI-generated clinical safety assertion within the provided text to be audited.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The only evaluated claims concern appropriate use for susceptible bacterial infections vs viral/nonbacterial infections, which is directly supported by the label excerpts provided. No contradictory or unsafe dosing/administration claims were present in the submitted text.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
No explicit mention of the boxed warning (C. difficile-associated diarrhea/colitis) in the provided claim text to evaluate.

Suggested Improvement
If producing a label-aligned response on safety, explicitly connect clindamycin use to considering CDAD risk and evaluating antibiotic-associated diarrhea/colitis as described in the boxed warning.